LLY
Eli Lilly and Company
LLY has the edge over QURE overall, supported by lower modeled downside and stronger fundamentals.
QURE
uniQure N.V.
QURE trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
QURE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Strong |
QURE's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
QURE PE Valuation
QURE has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
QURE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect QURE's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over QURE on earnings quality, reporting a profit while its opponent remains loss making.
QURE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.52 | +$0.86 |
| Q2 2026 | -$4.02 | -$0.11 |
| Q1 2026 | -$3.49 | +$0.89 |
| Q4 2025 | -$3.46 | +$1.46 |
| Q3 2025 | -$4.38 | +$0.57 |
| Q2 2025 | -$3.91 | +$2.01 |
| Q1 2025 | -$4.38 | +$1.82 |
| Q4 2024 | -$4.92 | +$1.55 |
QURE is still losing money, but less than at its worst: $3.52 per share over the past year, against $6.47 at its worst in late 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over QURE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over QURE on profitability, with a higher operating margin.
QURE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.2M | +40% |
| Q2 2026 | $5.8M | +11% |
| Q1 2026 | $3.6M | +127% |
| Q4 2025 | $5.6M | +6.6% |
| Q3 2025 | $3.7M | +62% |
| Q2 2025 | $5.3M | -53% |
| Q1 2025 | $1.6M | -82% |
| Q4 2024 | $5.2M | -22% |
QURE's revenue is recovering but still below its 2021 peak: $5M last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1020% | +359 points |
| Q2 2026 | -894% | -60 points |
| Q1 2026 | -1284% | +1226 points |
| Q4 2025 | -918% | -40 points |
| Q3 2025 | -1379% | +380 points |
| Q2 2025 | -834% | -438 points |
| Q1 2025 | -2510% | -1871 points |
| Q4 2024 | -878% | +45 points |
QURE's operating margin was −1020% last quarter, up 359 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over QURE on cash generation, producing positive trailing cash flow while its opponent burns cash.
QURE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.8M | -$31.5M |
| Q2 2026 | -$29M | +$11.1M |
| Q1 2026 | -$38.4M | +$5.8M |
| Q4 2025 | -$77.7M | -$24.8M |
| Q3 2025 | -$16.3M | +$20.6M |
| Q2 2025 | -$40.2M | -$6.8M |
| Q1 2025 | -$44.2M | +$18.7M |
| Q4 2024 | -$52.9M | -$1.3M |
QURE has burned cash in almost every quarter: −$193M over the past year, against −$154M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over QURE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
QURE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.5% | +3.7M shares |
| 1 year | +19% | +11.4M shares |
| 3 years | +46% | +22.1M shares |
| 5 years | +51% | +23.7M shares |
| Available history | +75% | +29.9M shares |
QURE has 70M diluted shares, up 19% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
QURE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -1.4x | Net Cash |
| Q4 2021 | -1.4x | Net Cash |
QURE has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
QURE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 10.8 | Oversold |
QURE's weekly RSI is 41 (neutral) and its Stochastic is 11 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
QURE PE vs Healthcare Sector
| Metric | QURE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
QURE has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over QURE on trend strength, trading above more of its moving averages.
QURE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.0 | 1.3% below |
| 20 week MA | $36.6 | 33% below |
| 50 week MA | $28.6 | 14% below |
| 100 week MA | $24.8 | 0.6% below |
| 200 week MA | $17.3 | 43% above |
QURE has fallen below most of its moving averages, though it's still 43% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over QURE on returns for 2026, with the stronger performance.
QURE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $72.5 | $38.1 | -47% |
| 2021 | $38.1 | $22.3 | -42% |
| 2022 | $22.3 | $23.3 | +4.7% |
| 2023 | $23.3 | $6.77 | -71% |
| 2024 | $6.77 | $17.5 | +158% |
| 2025 | $17.5 | $24.8 | +42% |
| 2026 YTD | $24.8 | $24.6 | -0.7% |
QURE's yearly returns have swung widely, from +158% in 2024 to −71% in 2023. It's down 0.7% so far in 2026.